Beta-1 adrenergic receptor antisense-oligodeoxynucleotides ameliorates left ventricular remodeling in 2-Kidney, 1-Clip rats.
Gene therapy has been applied to reduce blood pressure in rats. However, little is known about the effects of gene therapy on both blood pressure and left ventricular (LV) remodeling. This study was designed to compare the antihypertensive effect of ss(1) adrenergic receptor antisense oligodeoxynucleotides (ss(1)- AS-ODN) by delivery with the different charge ratios cationic liposomes DOTAP/DOPE and its impact on the LV remodeling in rats with 2-Kidney, 1-Clip (2K1C) Hypertension. Five charge ratios of liposome/ODN were tested in 2K1C rats. There was hypertension, cardiac dysfunction, LV hypertrophy and LV collagen deposition in 2K1C rats. On the basis of the magnitude and duration of hypotension, 2.0 was determined to be the optimal charge ratio, which decreased blood pressure by up to 39 mm Hg for 27 days. ss(1)-AS-ODN preserved cardiac function and inhibited LV mass and LV interstitial collagen deposition. In conclusion, cationic liposomes DOTAP/DOPE improve the antihypertensive effects of ss(1)-AS-ODN in renovascular hypertension and 2.0 were determined to be the optimal charge ratio. This study demonstrated that cardiac ss(1)-AR played a key role in LV remodeling and ss1-AS-ODN ameliorates cardiac dysfunction and LV remodeling.
Liang
Yuanhong
Y
Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangzhou, China.
Lin
Shuguang
S
Zhou
Yan
Y
Wang
Jinming
J
Yu
Xiyong
X
D000818:Animals; D001794:Blood Pressure; D015316:Genetic Therapy; D006977:Hypertension, Renal / Q000503:physiopathology / Q000628:therapy*; D008081:Liposomes; D008297:Male; D020319:Oligodeoxyribonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics; D020257:Ventricular Remodeling / Q000235:genetics
D008081:Liposomes; D020319:Oligodeoxyribonucleotides, Antisense; D018342:Receptors, Adrenergic, beta-1